Loading
A phase 2 trial of Purinostat in peripheral T-cell lymphomas, run by Chengdu Zenitar Biomedical Technology Co., Ltd, active and no longer recruiting.
A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma is a phase 2 interventional study registered as NCT06485219 by Chengdu Zenitar Biomedical Technology Co., Ltd, with 50 participants enrolled, started 2024-04-14 and due to reach its primary completion in 2026-06-30. Interventions recorded: 11.2 mg/m2 Purinostat Mesylate and 15 mg/m2 Purinostat Mesylate.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Purinostat, Chengdu Zenitar Biomedical Technology and the tag pipeline.
Shares Purinostat, Chengdu Zenitar Biomedical Technology and the tag pipeline.
Shares Chengdu Zenitar Biomedical Technology and the tag pipeline.
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Chengdu Zenitar Biomedical Technology and the tag pipeline.
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/